{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:52:07Z","timestamp":1787748727994,"version":"build-2784847793"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40801-023-00368-0","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T16:46:26Z","timestamp":1686069986000},"page":"415-428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Outcomes and Factors Associated with Insufficient Effectiveness of Acute Treatments of Migraine in Japan: Results of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study"],"prefix":"10.1007","volume":"10","author":[{"given":"Koichi","family":"Hirata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-1296","authenticated-orcid":false,"given":"Mika","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1967-9829","authenticated-orcid":false,"given":"Kaname","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Zagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-037X","authenticated-orcid":false,"given":"Dena H.","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Matsumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"issue":"1","key":"368_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, on behalf of Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0.","journal-title":"J Headache Pain"},{"issue":"1","key":"368_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-019-1012-1","volume":"20","author":"K Ueda","year":"2019","unstructured":"Ueda K, Ye W, Lombard L, Kuga A, Kim Y, Cotton S, et al. Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain. 2019;20(1):68. https:\/\/doi.org\/10.1186\/s10194-019-1012-1.","journal-title":"J Headache Pain"},{"key":"368_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2147\/NDT.S33769","volume":"9","author":"E Estemalik","year":"2013","unstructured":"Estemalik E, Tepper S. Preventive treatment in migraine and the new US guidelines. Neuropsychiatr Dis Treat. 2013;9:709\u201320. https:\/\/doi.org\/10.2147\/NDT.S33769.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"368_CR4","unstructured":"Headache Clinical Practice Guideline Development Committee. Clinical Practice Guideline for Headache Disorders 2021. Tokyo: Igaku-Shoin; 2021."},{"issue":"11","key":"368_CR5","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1080\/03007995.2021.1971179","volume":"37","author":"K Hirata","year":"2021","unstructured":"Hirata K, Ueda K, Komori M, Zagar AJ, Selzler KJ, Nelson AM, et al. Comprehensive population-based survey of migraine in Japan: results of the observational survey of the epidemiology, treatment, and care of migraine (OVERCOME [Japan]) study. Curr Med Res Opin. 2021;37(11):1945\u201355. https:\/\/doi.org\/10.1080\/03007995.2021.1971179.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"368_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1468-2982.1997.1701015.x","volume":"17","author":"F Sakai","year":"1997","unstructured":"Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17(1):15\u201322. https:\/\/doi.org\/10.1046\/j.1468-2982.1997.1701015.x.","journal-title":"Cephalalgia"},{"issue":"11","key":"368_CR7","doi-asserted-by":"publisher","first-page":"e038987","DOI":"10.1136\/bmjopen-2020-038987","volume":"10","author":"H Igarashi","year":"2020","unstructured":"Igarashi H, Ueda K, Jung S, Cai Z, Chen Y, Nakamura T. Social burden of people with the migraine diagnosis in Japan: evidence from a population-based cross-sectional survey. BMJ Open. 2020;10(11):e038987. https:\/\/doi.org\/10.1136\/bmjopen-2020-038987.","journal-title":"BMJ Open."},{"issue":"1","key":"368_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s10194-020-01180-9","volume":"21","author":"S Kikui","year":"2020","unstructured":"Kikui S, Chen Y, Todaka H, Asao K, Adachi K, Takeshima T. Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey. J Headache Pain. 2020;21(1):110. https:\/\/doi.org\/10.1186\/s10194-020-01180-9.","journal-title":"J Headache Pain"},{"issue":"1","key":"368_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s10194-021-01243-5","volume":"22","author":"T Shimizu","year":"2021","unstructured":"Shimizu T, Sakai F, Miyake H, Sone T, Sato M, Tanabe S, et al. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain. 2021;22(1):29. https:\/\/doi.org\/10.1186\/s10194-021-01243-5.","journal-title":"J Headache Pain"},{"issue":"1","key":"368_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40120-021-00305-9","volume":"11","author":"Y Matsumori","year":"2022","unstructured":"Matsumori Y, Ueda K, Komori M, Zagar AJ, Kim Y, Jaffe DH, et al. Burden of Migraine in Japan: results of the observational survey of the epidemiology, treatment, and care of migraine (OVERCOME [Japan]) Study. Neurol Ther. 2022;11(1):205\u201322. https:\/\/doi.org\/10.1007\/s40120-021-00305-9.","journal-title":"Neurol Ther."},{"issue":"5","key":"368_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/ncn3.12322","volume":"7","author":"N Araki","year":"2019","unstructured":"Araki N, Takeshima T, Ando N, Iizuka T, Igarashi H, Ikeda Y, et al. Clinical practice guideline for chronic headache 2013. Neurol Clin Neurosci. 2019;7(5):231\u201359. https:\/\/doi.org\/10.1111\/ncn3.12322.","journal-title":"Neurol Clin Neurosci"},{"issue":"11","key":"368_CR12","doi-asserted-by":"publisher","first-page":"5176","DOI":"10.1007\/s12325-022-02289-w","volume":"39","author":"T Takeshima","year":"2022","unstructured":"Takeshima T, Ueda K, Komori M, Zagar AJ, Kim Y, Jaffe DH, et al. Potential unmet needs in acute treatment of migraine in Japan: results of the OVERCOME (Japan) study. Adv Ther. 2022;39(11):5176\u201390. https:\/\/doi.org\/10.1007\/s12325-022-02289-w.","journal-title":"Adv Ther"},{"issue":"1","key":"368_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202.","journal-title":"Cephalalgia"},{"issue":"1","key":"368_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/jama.1992.03480010072027","volume":"267","author":"WF Stewart","year":"1992","unstructured":"Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267(1):64\u20139.","journal-title":"JAMA"},{"issue":"7","key":"368_CR15","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1046\/j.1526-4610.2001.041007646.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646\u201357. https:\/\/doi.org\/10.1046\/j.1526-4610.2001.041007646.x.","journal-title":"Headache"},{"issue":"2","key":"368_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/ana.21211","volume":"63","author":"R Lipton","year":"2008","unstructured":"Lipton R, Bigal M, Ashina S, Burstein R, Silberstein S, Reed M, et al. Cutaneous allodynia in the migraine population. Ann Neurol. 2008;63(2):148\u201358. https:\/\/doi.org\/10.1002\/ana.21211.","journal-title":"Ann Neurol"},{"issue":"7","key":"368_CR17","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/wnl.0000000000001256","volume":"84","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84(7):688\u201395. https:\/\/doi.org\/10.1212\/wnl.0000000000001256.","journal-title":"Neurology"},{"issue":"3","key":"368_CR18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1046\/j.1526-4610.2000.00030.x","volume":"40","author":"BC Martin","year":"2000","unstructured":"Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, et al. Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1). Headache. 2000;40(3):204\u201315. https:\/\/doi.org\/10.1046\/j.1526-4610.2000.00030.x.","journal-title":"Headache"},{"issue":"4","key":"368_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1526-4610.1998.3804295.x","volume":"38","author":"P Jhingran","year":"1998","unstructured":"Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L. Development and validation of the migraine-specific quality of life questionnaire. Headache. 1998;38(4):295\u2013302. https:\/\/doi.org\/10.1046\/j.1526-4610.1998.3804295.x.","journal-title":"Headache"},{"issue":"11","key":"368_CR20","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1468-2982.2009.01852.x","volume":"29","author":"JC Cole","year":"2009","unstructured":"Cole JC, Lin P, Rupnow MFT. Minimal important differences in the migraine-specific quality of life questionnaire (MSQ) version. Cephalalgia. 2009;29(11):1180\u20137. https:\/\/doi.org\/10.1111\/j.1468-2982.2009.01852.x.","journal-title":"Cephalalgia"},{"issue":"6","key":"368_CR21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2165\/00019053-199813060-00007","volume":"13","author":"P Jhingran","year":"1998","unstructured":"Jhingran P, Davis SM, LaVange LM, Miller DW, Helms RW. MSQ: migraine-specific quality-of-life questionnaire further investigation of the factor structure. Pharmacoeconomics. 1998;13(6):707\u201317. https:\/\/doi.org\/10.2165\/00019053-199813060-00007.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"368_CR22","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1023\/B:QURE.0000040787.20364.89","volume":"13","author":"S Ohbu","year":"2004","unstructured":"Ohbu S, Igarashi H, Okayasu H, Sakai F, Green J, Heller RF, et al. Development and testing of the Japanese version of the Migraine-Specific Quality of Life instrument. Qual Life Res. 2004;13(8):1489\u201393. https:\/\/doi.org\/10.1023\/B:QURE.0000040787.20364.89.","journal-title":"Qual Life Res"},{"key":"368_CR23","first-page":"449","volume":"21","author":"F Sakai","year":"2004","unstructured":"Sakai F, Fukuuchi Y, Iwata M, Nishimura S, Suzuki N, Igarashi H, et al. Reliability and validity of the Japanese version of the migraine quality of life survey [in Japanese]. Neurol Ther [Japan]. 2004;21:449\u201358.","journal-title":"Neurol Ther [Japan]."},{"issue":"6 Suppl 1","key":"368_CR24","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1212\/wnl.56.suppl_1.s20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl 1):S20\u20138. https:\/\/doi.org\/10.1212\/wnl.56.suppl_1.s20.","journal-title":"Neurology"},{"issue":"2","key":"368_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1468-2982.1999.019002107.x","volume":"19","author":"WF Stewart","year":"1999","unstructured":"Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia. 1999;19(2):107\u201314. https:\/\/doi.org\/10.1046\/j.1468-2982.1999.019002107.x.","journal-title":"Cephalalgia"},{"issue":"4","key":"368_CR26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1046\/j.1526-4610.2003.03069.x","volume":"43","author":"M Iigaya","year":"2003","unstructured":"Iigaya M, Sakai F, Kolodner KB, Lipton RB, Stewart WF. Reliability and validity of the Japanese migraine disability assessment (MIDAS) questionnaire. Headache. 2003;43(4):343\u201352.","journal-title":"Headache"},{"key":"368_CR27","first-page":"A89","volume":"68","author":"DC Buse","year":"2007","unstructured":"Buse DC, Bigal MB, Rupnow M, Reed M, Serrano D, Lipton R. Development and validation of the Migraine Interictal Burden Scale (MIBS): a self-administered instrument for measuring the burden of migraine between attacks [abstract S05.003]. Neurology. 2007;68:A89.","journal-title":"Neurology"},{"issue":"5","key":"368_CR28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4065\/84.5.422","volume":"84","author":"DC Buse","year":"2009","unstructured":"Buse DC, Rupnow MFT, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84(5):422\u201335. https:\/\/doi.org\/10.4065\/84.5.422.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"368_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"368_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-020-01110-9","volume":"21","author":"L Lombard","year":"2020","unstructured":"Lombard L, Farrar M, Ye W, Kim Y, Cotton S, Buchanan AS, et al. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J Headache Pain. 2020;21(1):41. https:\/\/doi.org\/10.1186\/s10194-020-01110-9.","journal-title":"J Headache Pain"},{"issue":"1","key":"368_CR31","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40122-020-00223-y","volume":"10","author":"K Hirata","year":"2021","unstructured":"Hirata K, Ueda K, Komori M, Ye W, Kim Y, Cotton S, et al. Unmet needs in Japanese patients who report insufficient efficacy with triptans for acute treatment of migraine: retrospective analysis of real-world data. Pain Ther. 2021;10(1):415\u201332. https:\/\/doi.org\/10.1007\/s40122-020-00223-y.","journal-title":"Pain Ther"},{"issue":"8","key":"368_CR32","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/head.13897","volume":"60","author":"SJ Tepper","year":"2020","unstructured":"Tepper SJ, Vasudeva R, Krege JH, Rathmann SS, Doty E, Vargas BB, et al. Evaluation of 2-hour post-dose efficacy of lasmiditan for the acute treatment of difficult-to-treat migraine attacks. Headache. 2020;60(8):1601\u201315. https:\/\/doi.org\/10.1111\/head.13897.","journal-title":"Headache"},{"issue":"5","key":"368_CR33","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.pec.2015.02.013","volume":"98","author":"M Suka","year":"2015","unstructured":"Suka M, Odajima T, Okamoto M, Sumitani M, Igarashi A, Ishikawa H, et al. Relationship between health literacy, health information access, health behavior, and health status in Japanese people. Patient Educ Couns. 2015;98(5):660\u20138. https:\/\/doi.org\/10.1016\/j.pec.2015.02.013.","journal-title":"Patient Educ Couns"},{"issue":"1","key":"368_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10194-021-01265-z","volume":"22","author":"TJ Steiner","year":"2021","unstructured":"Steiner TJ, Jensen R, Katsarava Z, Stovner LJ, Uluduz D, Adarmouch L, et al. Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description. J Headache Pain. 2021;22(1):78. https:\/\/doi.org\/10.1186\/s10194-021-01265-z.","journal-title":"J Headache Pain."},{"issue":"1","key":"368_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s10194-021-01310-x","volume":"22","author":"M Tinelli","year":"2021","unstructured":"Tinelli M, Leonardi M, Paemeleire K, Mitsikostas D, de la Torre ER, Steiner TJ. Structured headache services as the solution to the ill-health burden of headache. 2. Modelling effectiveness and cost-effectiveness of implementation in Europe: methodology. J Headache Pain. 2021;22(1):99. https:\/\/doi.org\/10.1186\/s10194-021-01310-x.","journal-title":"J Headache Pain"},{"issue":"1","key":"368_CR36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-021-01305-8","volume":"22","author":"M Tinelli","year":"2021","unstructured":"Tinelli M, Leonardi M, Paemeleire K, Raggi A, Mitsikostas D, de la Torre ER, et al. Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: findings and conclusions. J Headache Pain. 2021;22(1):90. https:\/\/doi.org\/10.1186\/s10194-021-01305-8.","journal-title":"J Headache Pain"},{"issue":"S3","key":"368_CR37","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1017\/S0317167100118943","volume":"40","author":"I Worthington","year":"2013","unstructured":"Worthington I, Pringsheim T, Gawel MJ, Gladstone J, Cooper P, Dilli E, et al. Canadian headache society guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013;40(S3):S1\u20133. https:\/\/doi.org\/10.1017\/S0317167100118943.","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"368_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1129-2377-15-2","volume":"15","author":"M Lanteri-Minet","year":"2014","unstructured":"Lanteri-Minet M, Valade D, Geraud G, Lucas C, Donnet A. Revised French guidelines for the diagnosis and management of migraine in adults and children. J Headache Pain. 2014;15(1):2. https:\/\/doi.org\/10.1186\/1129-2377-15-2.","journal-title":"J Headache Pain"},{"issue":"1","key":"368_CR39","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1177\/2514183X18823377","volume":"3","author":"H-C Diener","year":"2019","unstructured":"Diener H-C, Holle-Lee D, N\u00e4gel S, Dresler T, Gaul C, G\u00f6bel H, et al. Treatment of migraine attacks and prevention of migraine: guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clin Trans Neurosci. 2019;3(1):2514. https:\/\/doi.org\/10.1177\/2514183X18823377.","journal-title":"Clin Trans Neurosci"},{"issue":"1","key":"368_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s10194-018-0899-2","volume":"20","author":"TJ Steiner","year":"2019","unstructured":"Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain. 2019;20(1):57. https:\/\/doi.org\/10.1186\/s10194-018-0899-2.","journal-title":"J Headache Pain"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-023-00368-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-023-00368-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-023-00368-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T17:12:34Z","timestamp":1694193154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-023-00368-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["368"],"URL":"https:\/\/doi.org\/10.1007\/s40801-023-00368-0","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,6]]},"assertion":[{"value":"12 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: MK, KU. Data curation: AJZ, YK, DHJ. Formal analysis: AJZ, YK. Funding acquisition: MK, KU. Investigation: DHJ. Methodology: AJZ, YK, DHJ. Project administration: MK, KU. Resources: DHJ. Software: AJZ, YK. Supervision: KH, YM, TT. Validation: AJZ, YK, DHJ. Visualization: MK, KU. Writing review and editing: MK, KU, DHJ, AJZ, YK, KH, YM, TT. All authors read and approved the final version.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This study was sponsored by Eli Lilly and Company and operated by Cerner Enviza, an Oracle company (formerly Kantar Health). Medical writing assistance was provided by Koa Webster, Ph.D., and Prudence Stanford, Ph.D., CMPP, of ProScribe\u2014Envision Pharma Group, and was funded by Eli Lilly Japan K.K. and Daiichi Sankyo Company, Limited. ProScribe\u2019s services complied with international guidelines for Good Publication Practice.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Koichi Hirata received research funding from the Japan Agency for Medical Research and Development and the Japanese Ministry for Health, Labour and Welfare and personal fees from Amgen Astellas BioPharma K.K.; Daiichi Sankyo Company, Limited; Eisai Co., Ltd.; Eli Lilly Japan K.K.; MSD Co., Ltd.; Otsuka Pharmaceutical Co., Ltd.; and Pfizer Japan Inc. Mika Komori and Kaname Ueda are employees of Eli Lilly Japan K.K. and own minor shares in Eli Lilly and Company. Anthony J. Zagar is an employee and minor shareholder of Eli Lilly and Company. At the time of the study, Yongin Kim was an employee and minor shareholder of Eli Lilly and Company. Dena H. Jaffe is an employee of Cerner Enviza, an Oracle company (formerly Kantar Health); Cerner Enviza, an Oracle company, received research funding for this study from Eli Lilly and Company. Yasuhiko Matsumori received personal consultancy fees from Amgen Astellas BioPharma K.K.; Daiichi Sankyo Company, Limited; Eli Lilly Japan K.K.; and Otsuka Pharmaceutical Co., Ltd. Takao Takeshima received personal fees from AbbVie GK; Amgen Astellas BioPharma K.K.; Asahi Kasei Pharma Corporation; Bayer Yakuhin, Ltd; Daiichi Sankyo Company, Limited; Eli Lilly Japan K.K.; Fujifilm Toyama Chemical Co., Ltd.; Janssen Pharmaceutical K.K.; Kowa Company, Ltd.; Kyowa Kirin Co., Ltd.; Lundbeck Japan K.K.; Mitsubishi Tanabe Pharma Corporation; Novartis Pharma K.K.; Ono Pharmaceutical Co., Ltd; Otsuka Pharmaceutical Co., Ltd.; Pfizer Japan Inc.; Sawai Pharmaceutical Co., Ltd.; Sumitomo Dainippon Pharma Co. Ltd.; and UCB Japan Co. Ltd. He also received personal fees from Takeda Pharmaceutical Company Limited outside the submitted work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval for the study was granted by the Research Institute of Healthcare Data Science Ethical Review Board (ID: RI2020003).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All survey respondents provided electronic informed consent, and all data were anonymized before analysis.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Eli Lilly and Company was involved in the study design, data analysis, and preparation of the manuscript. Cerner Enviza, an Oracle company, (formerly Kantar Health) was involved in the study design, data collection, data analysis, and preparation of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the sponsor"}}]}}